Letrozol Teva-Ratiopharm

Letrozole, the active ingredient in Letrozol Teva‑Ratiopharm, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat postmenopausal estrogen receptor‑positive breast cancer by lowering estrogen production.

GNH USA supplies Letrozol Teva‑Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance. The company ensures consistent product availability, adheres to Good Manufacturing Practices, and provides comprehensive technical support to its global partners.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven disease pathways. - Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor growth by lowering circulating estrogen levels. - Adjuvant therapy for hormone receptor‑positive breast cancer: helps prevent disease recurrence after surgery. - Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival outcomes.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild to moderate stomach upset.

Serious or Rare Side Effects: - Severe liver injury: elevated liver enzymes or hepatitis. - Bone fracture: increased risk of osteoporosis‑related fractures. - Allergic reaction: rash, swelling, or anaphylaxis.

Before initiating letrozole therapy, clinicians should consider several precautionary measures to ensure patient safety. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: evaluate hepatic enzymes prior to treatment and periodically thereafter. - Cardiovascular risk evaluation: review history of thromboembolic events or uncontrolled hypertension. - Drug interaction review: check concomitant medications for potential interactions affecting letrozole metabolism. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma levels. - Anticoagulants (e.g., warfarin): increased risk of bleeding due to altered metabolism. - Tamoxifen: concurrent use may antagonize therapeutic effects.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may modestly increase letrozole concentrations. - Hormone replacement therapy: may diminish letrozole’s estrogen‑lowering action.